Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies†

Preshendren Govender,a Tina Riedel,b Paul J. Dysonb and Gregory S. Smith*a

A new series of eight first- and second-generation heterometallic ferrocenyl-derived metal–arene metallo-dendrimers, containing ruthenium(II)–p-cymene, ruthenium(II)–hexamethylbenzene, rhodium(II)–cyclopentadienyl or iridium(III)–cyclopentadienyl moieties have been prepared. The metallo-dendrimers were synthesized by first reacting DAB–(NH₂)n (where n = 4 or 8, DAB = diaminobutane) with salicylaldehyde, and then the Schiff-base dendritic ligands were reacted in a one-pot reaction with the appropriate [η₆–p–iPrC₆H₄Me]RuCl₂₂, [η₆–C₆Me₆]RuCl₂₂, [η₆–C₅Me₅]IrCl₂₂ or [η₆–C₅Me₅]RhCl₂₂ dimers, in the presence of 4-pyridylferrocene. Heterometallic binuclear analogues were prepared as models of the larger metallo-dendrimers. All complexes have been characterized using analytical and spectroscopic methods. The cytotoxicity of the heterometallic metallo-dendrimers and their binuclear analogues were evaluated against A2780 cisplatin-sensitive and A2780cisR cisplatin-resistant human ovarian cancer cell lines and against a non-tumorigenic HEK-293 human embryonic kidney cell line. The second generation Ru(II)–η₆–C₆Me₆ metallo-dendrimer is the most cytotoxic and selective compound. DNA binding experiments reveal that a possible mode-of-action of these compounds involves non-covalent interactions with DNA.

Introduction

Research on the design of heterometallic complexes as possible anticancer agents has flourished.1–6 Due to its favourable electronic properties and ease of functionalization,7–12 ferrocene has been incorporated in various biologically active systems,9,13,14 in an effort to achieve a synergistic effect between the metal centers.15–20 Furthermore, simple derivatives of ferrocene display good activity in vitro, with inhibition of tumors observed in vivo.21,22 In the search for new tamoxifen-like drugs, Jaouen and co-workers23,24 prepared ferrocifen from 1-[4-(2-dimethylaminoethoxy)]-1-(phenyl-2-ferrocenylbut-1-ene), which are highly active ferrocenyl-derivatives of the purely organic breast cancer drug tamoxifen. The increase in activity is attributed to the dual action of the organic drug and the Fenton chemistry (i.e. formation of singlet oxygen) of the Fe centre.25,26 Moreover, the stability of ferrocene in aqueous and aerobic media, the facility with which a large variety of derivatives may be prepared, and its favorable electrochemical properties, has resulted in ferrocene becoming a promising molecule for incorporating in biological applications.12 Furthermore, certain ferrocene-containing compounds exhibit cytotoxicities comparable to the benchmark anticancer drug, cisplatin.

Due to the undesirable side-effects displayed by platinum-based anticancer drugs,27,28 researchers have turned their attention to other metals.29,30 One such metal is ruthenium, as ruthenium complexes tend to be less cytotoxic in comparison to platinum compounds,31 and two promising Ru(II) anticancer agents are undergoing clinical trials.32–35 The activity of the Ru(II) anticancer agents is thought to be brought about by reduction of the compounds to a Ru(n) species in vivo,33 and consequently there is a growing interest in the preparation and biological evaluation of ruthenium(n)-arene complexes.36–42 Two anticancer agents are at the forefront of this promising class of organometallic compounds, RAED-C [(η₆–p-cym)Ru(ethylene-diamine)Cl]PF₆43,44 and RAPTA-C [(η₆–p-cym)Ru(1,3,5-triazalo-7-phosphaadamantane)Cl]₄₅,₄₆ The former is a cytotoxic compound that binds preferentially to DNA,47 whereas the latter is a non-cytotoxic antitumor compound,46,48–51 that displays an antiangiogenic effect52 and

*Department of Chemistry, University of Cape Town, Rondebosch, 7701, Cape Town, South Africa. Fax: +27-21-6505195; E-mail: gregory.smith@uct.ac.za
†Institut des Sciences et Ingénierie Chimique, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
‡Electronic supplementary information (ESI) available. See DOI: 10.1039/c6dt00849f
bonds preferentially to histone proteins. In addition, a host of Rh(η5-C5Me5) and Ir(η5-C5Me5) derivatives have previously demonstrated pharmacological properties, which promote further study of these compounds.

The concept of combining organometallic complexes with compounds of known therapeutic value is a growing area of research, and coupled with the notion of multinuclearity that can result in enhanced therapeutic activity, the combination is an attractive drug-design strategy. Moreover, one way of introducing the notion of multinuclearity is to conjugate therapeutic agents onto dendritic scaffolds that could potentially exploit the enhanced permeability and retention (EPR) effect.

Recently, we reported tetranuclear and octanuclear N,O- and N,N-ruthenium–arene metallodendrimers, with ferrocene moieties functionalized on the periphery of the dendritic scaffold. The majority of the compounds efficiently inhibit the growth of both A2780 cisplatin-sensitive and A2780cisR cisplatin-resistant human ovarian cancer cells (i.e. IC50 < 5 μM). In addition, these complexes displayed no cross-resistance to cisplatin, with the metallodendrimers having a better activity compared to their mononuclear complexes.

On the basis of the above observed results we hypothesized that preparing ferrocenyl-derived metal-arene metallodendrimers, where the ferrocene moiety is coordinated directly to the metal center rather than on the periphery, may further enhance the antiproliferative activity of the compounds. In this study, we describe the synthesis of a series of bidentate ferrocenyl-derived dendrimers containing ruthenium(η5)-p-cymene, ruthenium(η5)-HMB (where HMB = hexamethylbenzene), rhodium(η5)-Cp* or iridium(η5)-Cp* (where Cp* = cyclopentadienyl) moieties [1][PF6]4-[8][PF6]8 (see Scheme 1). The cytotoxicity of the complexes was evaluated against the A2780 and the A2780cisR human ovarian cancer cell lines, as well as against the non-cancerous human embryonic kidney (HEK-293) cell line. In order to investigate whether the antiproliferative activity is size-dependent, binuclear model analogues [9][PF6]4-[12][PF6]8 were also prepared and evaluated.

Results and discussion

Synthesis of ferrocenyl-derived heterometallic metallodendrimers

Ferrocenyl-derived heterometallic metallodendrimers [1][PF6]4-[8][PF6]8 were prepared from the dinuclear precursors [([η5-p-iPrC6H4Me]RuCl2)2, ([η5-C6Me6]RuCl2)2, ([η5-C5Me5)IrCl2]2 or ([η5-C5Me5)RhCl3]2 and 4-ferrocenylpyridine, in the presence of Et3N, functionalized onto known first- and second-generation salicyaldiminepoly(propyleneimine) dendritic ligands (L1, L2) (Scheme 1). The metallodendrimers were isolated in moderate yields as hexafluorophosphate salts via a metathesis reaction. Compounds [1][PF6]4-[8][PF6]8 are non-hygrosopic, air- and moisture-stable orange solids, and are soluble in dimethylsulfoxide, acetonitrile or acetone.

Compared to non-ferrocenyl neutral derivatives previously reported, the 1H NMR spectra of [1][PF6]4-[8][PF6]8 show a general downfield shift in signals due to the cationic nature of the complexes. More specifically, the imine proton appears slightly more downfield from ca. 7.9 ppm (in the neutral complex) to ca. 8.2 ppm (in the cationic complex). The shift in the imine proton, the general downfield shift of the aromatic protons and the disappearance of the phenolic proton for [1][PF6]4-[8][PF6]8 compared to the free ligands L1 and L2, suggests coordination to the metal ion via the imine nitrogen and phenolic oxygen. The protons on the substituted Cp rings (of the ferrocenylpyridine moiety) are assigned to the broad singlet and two broad multiplets appearing in the region between 4.0 and 5.0 ppm for [1][PF6]4-[8][PF6]8 compared to the free ligands L1 and L2. The aliphatic protons of the dendritic core and dendritic arms occur as broadened peaks, between 1.2 ppm and 3.0 ppm and at similar chemical shifts to those of the dendri-

![Scheme 1](image-url)
tic ligands L1 and L2. All metallodendrimers [1][PF6]4–[8][PF6]8 show a loss of two-fold symmetry around the metal center upon coordination of the N,C-dendritic ligand. Evidence for this is provided by the presence of two sets of signals (one of the signals is masked by the singlet observed for the un-substituted Cp ring) for the –CH2– group adjacent to the imine nitrogen, due to the diastereotopic nature of these protons induced by the chiral metal center. As a result, the methyl protons of the isopropyl group, on the aren ring, of the Ru–p-cymene metallodendrimers [1][PF6]4 and [2][PF6]8 exhibit two broad doublets in the range of 1.2–1.3 ppm. A broad singlet is observed at 2.0 ppm (for [3][PF6]4 and [4][PF6]8) and at 1.6 ppm (for [5][PF6]4 and [8][PF6]8) for the HMB and Cp* protons, respectively.

The infrared spectra of metallodendrimers [1][PF6]4–[8][PF6]8 display a shift for the (C=N)imine stretching vibration from ca. 1630 cm$^{-1}$ in the ligand (L1 or L2), to lower wavenumbers ca. 1611 cm$^{-1}$, supporting coordination of the ligand to the metal center via the imine nitrogen. This stretching vibration also overlaps with the vibration observed for the (C=N)pyridyl on the ferrocenylpyridine moiety. Inclusion of solvent molecules resulted in elemental analysis data for [1][PF6]4–[8][PF6]8 to within acceptable limits, and is similarly observed with other previously reported metallodendrimers.$^{72,81}$ High-resolution mass spectrometry data (run in the positive-ion mode) is consistent with the proposed structures of [1][PF6]4–[8][PF6]8, with a base peak observed corresponding to a charged adduct.

**Synthesis of ferrocenyl-derived heterometallic binuclear complexes**

Binuclear model complexes [9][PF6]4–[12][PF6]8 were prepared to evaluate whether there is a size dependency correlation between the complexes prepared and their biological activity (see below). Two equivalents of the monomeric ligand L3,$^{94}$ were reacted with one equivalent of the particular metal-dimer, in the presence of triethylamine, in a one-pot reaction (Scheme 2). Subsequently, 4-ferrocenylpyridine was added to the reaction mixture, which generated a cationic complex, and the products were isolated as red or red-orange hexafluorophosphate salts. The binuclear model complexes have similar solubilities to their dendritic derivatives [1][PF6]4–[8][PF6]8. Furthermore, the synthesis and purity of the heterometallic model (analouges [9][PF6]4–[12][PF6]8 were confirmed by $^1$H, $^{13}$C ($^1$H) NMR and infrared spectroscopy, elemental analysis and mass spectrometry.

**Biological activity**

The antiproliferative activity of the cationic metaldendrimers [1][PF6]4–[8][PF6]8 and the model compounds [9][PF6]4–[12][PF6]8 was established in vitro against the human ovarian cisplatin-sensitive (A2780) and cisplatin-resistant (A2780cisR) cancer cell lines and against the non-tumorigenic human embryonic kidney (HEK-293) cell line (Table 1). The model complexes [9][PF6]4–[12][PF6]8 display modest activity in both cancer cell lines and, notably, they are not cancer cell selective. However, there is a considerable increase in cytotoxicity on moving to the higher generation compounds, in particular, for the ferrocenyl-derivered Ru–HMB metallodendrimers ([3][PF6]4 and [4][PF6]8) and Rh– Cp* ([7][PF6]4 and [8][PF6]8). The first-generation metallodendrimers [3][PF6]4 (9.1 μM in A2780; 5.9 μM in A2780cisR) and [7][PF6]4 (6.1 μM in A2780; 12.7 μM in A2780cisR) and second-generation metallodendrimers

**Table 1** IC$_{50}$ values of [9][PF6]4–[12][PF6]8 against A2780 and A2780cisR human ovarian cancer cells and non-tumorigenic HEK-293 human embryonic kidney cells

| Compound | M$^a$ | A2780 (IC$_{50}$, μM) | A2780cisR (IC$_{50}$, μM) | HEK-293 (IC$_{50}$, μM) |
|----------|-------|------------------------|--------------------------|------------------------|
| [1][PF6]4 | Ru–Fe | 107.2 ± 2.0 | 53.3 ± 0.1 | 138.3 ± 7.3 |
| [2][PF6]8 | Ru–Fe | 26.6 ± 1.0 | 44.1 ± 1.7 | 20.3 ± 1.5 |
| [3][PF6]4 | Ru–Fe | 8.9 ± 0.3 | 5.9 ± 0.1 | 11.6 ± 1.1 |
| [4][PF6]8 | Ru–Fe | 4.7 ± 0.2 | 3.5 ± 0.2 | 5.7 ± 0.2 |
| [5][PF6]4 | Ir–Fe | 46.4 ± 2.5 | 59.0 ± 0.6 | 35.9 ± 3.4 |
| [6][PF6]8 | Ir–Fe | 11.7 ± 0.3 | 7.6 ± 1.3 | 13.6 ± 2.0 |
| [7][PF6]4 | Rh–Fe | 6.1 ± 0.1 | 12.7 ± 1.0 | 19.0 ± 0.6 |
| [8][PF6]8 | Rh–Fe | 10.7 ± 1.3 | 7.9 ± 0.4 | 9.4 ± 1.4 |
| [9][PF6]4 | Ru–Fe | 29.2 ± 1.7 | 33.0 ± 2.4 | 28.7 ± 0.6 |
| [10][PF6]8 | Ru–Fe | 9.7 ± 1.3 | 17.4 ± 1.0 | 16.1 ± 1.5 |
| [11][PF6]4 | Ir–Fe | 39.6 ± 3.0 | 36.7 ± 0.2 | 31.1 ± 0.3 |
| [12][PF6]8 | Rh–Fe | 59.0 ± 0.3 | 72.9 ± 0.3 | 65.5 ± 3.3 |

| Pt | cisplatin |
|---|---|
| 1 | 1.5 ± 0.5 | 25.0 ± 5.0 | 10.0 ± 2.0 |

$^a$Type of metal(s) present in the complex. $^b$Number of metals within the complex.

**Scheme 2** Synthesis of ferrocenyl-derived heterometallic mononuclear complexes [9][PF6]4–[12][PF6]8.

![Synthesis of ferrocenyl-derived heterometallic mononuclear complexes](image-url)
[4][PF₆]₈ (4.7 μM in A2780; 3.5 μM in A2780cisR), [6][PF₆]₈ (11.7 μM in A2780; 7.6 μM in A2780cisR) and [8][PF₆]₈ (10.7 μM in A2780; 7.9 μM in A2780cisR) are the most active of the series. With the exception of the p-cymene metallodendrimers [1][PF₆]₈ and [2][PF₆]₈, and the first-generation Ir– Cp* metallodendrimer [5][PF₆]₈, the metallodendrimers have similar cytotoxicities in both the sensitive and resistant cancer cell lines, indicating that these compounds operate via a different mechanism of action to that of cisplatin. Similar, IC₅₀ values were previously observed for the p-cymene derivatives (where ferrocene is functionalized onto the periphery of the metallodendrimer),⁸¹ were also observed for the p-cymene derivatives [1][PF₆]₈ and [2][PF₆]₈, where the ferrocene moiety is directly coordinated to the ruthenium center. The introduction of the ferrocenyl moiety results in comparable cytotoxicities for the Rh and Ir metallodendrimers reported here, to their neutral RhCp*Cl and IrCp*Cl analogues reported previously.⁷⁴ However, incorporation of pyridylferrocene group on [7][PF₆]₄ improves the activity of the compound compared to the first generation neutral Rh–Cp*Cl analogue (55 μM in A2780 and 126 μM in A2780cisR).⁷⁴ Similarly, an improvement in activity for the cationic ferrocenyl-derived Ru–HMB metallodendrimers [3][PF₆]₄ and [4][PF₆]₈ was observed compared to their neutral Ru–HMB-Cl analogs (G1-Ru–HMB-Cl = 27 μM (A2780); 25 μM (A2780cisR); G2-Ru–HMB-Cl = 10 μM (A2780); 10 μM (A2780cisR) reported previously),⁸³ with comparable activities to their cationic Ru–HMB-PTA analogs (G1-Ru–HMB-PTA = 9 μM (A2780); 25 μM (A2780cisR); G2-Ru–HMB-PTA = 6 μM (A2780); 12 μM (A2780cisR)).⁷³ There is a correlation between the size-dependency of the metallodendrimers and the cytotoxicity, with metallodendrimers [3][PF₆]₄ and [4][PF₆]₈ being the only compounds to exhibit a significant degree of cancer cell selectivity. A direct comparison between these systems (ferrocene at the metal center) and the previously prepared systems (ferrocene at the periphery)⁸¹ cannot be made as different in vitro biological studies were performed. However, coordination of the pyridylferrocene moiety to the Ru center affords more cytotoxic compounds.

NMR stability study

Compound stability is important for biological applications and, in the case of metal-based drugs, many compounds are actually prodrugs and hence the identity of the compound that reaches the cell can be important. Following uptake into the cell, related ruthenium–arene-PTA complexes are activated via aquation, generating the aqua species, a process that can be monitored by NMR spectroscopy.⁸⁵,⁸⁶ Furthermore, to investigate the influence of the bidentate chelating N,O-dendritic ligands on the stability of the metallodendrimers in solution and to mimic the preparation of solutions prior to biological assays, aqueous stability studies were performed on selected complexes, in a mixture of DMSO-d₆ : D₂O (50 : 50% v/v) at 37 °C, using ¹H NMR spectroscopy. The HMB-derivatives display the best in vitro activity, thus, the second-generation metallodendrimer [4][PF₆]₈ and its closest binuclear model analogue [10][PF₆] were selected, and studies were undertaken in DMSO-d₆ : D₂O (50 : 50% v/v) over 24 hours at 37 °C (Fig. 1).

The ¹H NMR spectra of [4][PF₆]₈ and [10][PF₆] (Fig. 1) show that the compounds are stable in solution, with no side-products or the formation of the aqua-species observed over a period of 24 hours. In addition, these data show that the complexes are stable in deuterated dimethylsulfoxide, relevant during the time period between preparation of the compound stock solutions and dosing of the cancer cells in the assay.

Fig. 1 ¹H NMR spectra of [4][PF₆]₈ (top three spectra) and [10][PF₆] (bottom 5 spectra) in DMSO-d₆ : D₂O (50 : 50% v/v) over 24 hours at 37 °C.
UV-Vis study: interactions with a DNA model

DNA is a potential drug target for ruthenium–arene compounds and is an important target in cancer therapy. Furthermore, some of the most cytotoxic ruthenium drugs act as DNA intercalators upon coordination to the suitable ancillary ligand. In order to correlate the antiproliferative activity of the metallodendrimers to possible interactions with DNA, a UV-vis study was performed. The interactions of [4][PF6]8 (the most active compound) and its model analogue [10][PF6] were selected for the study and their interaction with Red Salmon testes DNA monitored by UV-vis spectroscopy (Fig. 2).

The UV-vis spectra for both [4][PF6]8 and [10][PF6] display hypochromic shifts (upon DNA addition) as the absorbance at $\lambda_{\text{max}} = 320$ nm (for [4][PF6]8) and $\lambda_{\text{max}} = 310$ nm (for [10][PF6]) decrease, with no substantial red- or blue-shift observed for $\lambda_{\text{max}}$ for both systems (Fig. 2). Similar hypochromic shifts were reported with Cu(II), Co(II) and Ni(II) complexes upon addition of increasing concentration of DNA, whereas norepinephrine (DNA binding agent) displays a hyperchromic shift upon DNA addition. A hyperchromic shift is usually associated with the partial uncoiling of the DNA double helix, which exposes more of the DNA base-pairs, which in turn results in the increase in absorbance at $\lambda_{\text{max}}$. However, hypochromic effects are also associated with non-covalent interactions between the complex and DNA, such as intercalative binding, indicating that DNA could be a relevant target for these compounds.

Conclusions

A series of bidentate heterometallic ferrocenyl-derived dendrimers containing ruthenium(u)–p-cymene, ruthenium(u)–HMB, rhodium(u)–cyclopentadienyl or iridium(u)–cyclopentadienyl moieties have been successfully synthesized and characterized. Heterometallic model complexes were also prepared and characterized (for comparison with the larger metallodendrimers). Antiproliferative studies performed on the metallodendrimers and the model binuclear complexes show that the model complexes display limited activity, whereas the metallodendrimers display higher cytotoxicities, particularly the second-generation ferrocenyl-derived ruthenium(u)–hexamethylbenzene metallodendrimer, which displayed the best activity of the series. The presence of ferrocene leads to more cytotoxic compounds compared to previously reported non-ferrocenyl derivatives. In addition, these metallodendrimers displayed no cross-resistance to cisplatin and some are cancer cell selective, being less cytotoxic to the non-tumorigenic cells included in the study. Spectroscopic studies illustrate that these systems are stable in solution and additional DNA binding studies suggest that a possible mode-of-action of these metallodendrimers (at least for the most active derivative) involves possible non-covalent interactions (illustrated by UV-vis experiments) with the DNA.

Experimental

General details

All solvents and reagents were purchased from Sigma-Aldrich; DAB-G2-PPi-(NH2)8 was purchased from SyMO-Chem and used without further purification. Ruthenium trichloride trihydrate, iridium trichloride trihydrate and rhodium trichloride trihydrate were obtained from Heraeus Limited. L1, L2, L3, [(η5-p-tBuC5H4Me)RuCl2]2, [(η5-C5Me5)RuCl2]2, [(η5-C5Me5)IrCl2]2, [(η5-C6Me6)RhCl2]2 and 4-ferrocenylpyridine (4-FePy) were prepared according to literature procedures. Infrared (IR) spectra determined in the solid state on a Perkin-Elmer Spectrum 100 FT-IR spectrometer equipped with a SMART iTR ATR unit. The intensity of stretching vibrations are
marked as strong (s), medium (m) and weak (w). Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Mercury XR300 spectrometer (1H: 300.08 MHz; 13C(1H): 75.46 MHz) or Bruker Biospin GmbH spectrometer (1H: 400.22 MHz; 13C(1H): 100.65 MHz) at ambient temperature. Chemical shifts δ in ppm indicate a downfield shift relative to tetramethylsilane (TMS) and were referenced relative to the signal of the solvent. Individual peaks are marked as singlet (s), doublet (d), doublet-of-doublet (dd), triplet (t), or multiplet (m). High-resolution electrospray ionization-mass spectrometry (HR-ESI-MS) was carried out on a Waters Synapt mass spectrometer. Data were recorded in positive ion mode. Elemental analysis (C, H, N) was carried out using a Thermo Flash 1112 Series CHNS-O Analyzer. For certain metalloendrimers, the analyses are outside acceptable limits, which is ascribed to the encapsulation of solvent molecules and/or other inorganic salts by the dendritic compounds. UV–vis absorption studies were carried out on a Cary UV-vis spectrophotometer using a 1 cm path length quartz cuvette to carry out the measurements.

**Compound synthesis**

General synthesis of cationic N,O-(η^6-arene)-Ru(II)-ferrocenylpyridine metalloendendrimers ([][PF6]4-[4][PF6]4). Triethylamine (0.038 mL, 0.263 mmol for [][PF6]4; 0.036 mL, 0.258 mmol for [2][PF6]4; 0.035 mL, 0.254 mmol for [3][PF6]4; 0.037 mL, 0.265 mmol for [4][PF6]4) was added to a stirred suspension of L1 (0.0476 g, 0.0649 mmol for [][PF6]4; 0.0460 g, 0.0628 mmol for [2][PF6]4) or L2 (0.0514 g, 0.0320 mmol for [2][PF6]4; 0.0528 g, 0.0329 mmol for [4][PF6]4) in a EtOH:DCM (50:50, 30 mL) mixture. The resulting yellow-suspension was stirred at room temperature for 0.5 hours. Next, [[η^6-p-PrC6H4Me]2RuCl2]2 (0.0815 g, 0.133 mmol for [][PF6]4; 0.0794 g, 0.130 mmol for [2][PF6]4) or [[η^6-C6Me6]2RuCl2]2 (0.0870 g, 0.129 mmol for [3][PF6]4; 0.0901 g, 0.133 mmol for [4][PF6]4) was added to the reaction mixture. The reaction mixture was stirred overnight at room temperature, then, the reaction mixture was filtered and the filtrate reduced to ca. 5 mL. This was followed by the addition 4-ferrocenylpyridine (0.0692 g, 0.263 mmol for [][PF6]4; 0.0678 g, 0.258 mmol for [2][PF6]4; 0.0669 g, 0.254 mmol for [3][PF6]4; 0.0696 g, 0.265 mmol for [4][PF6]4) and the solution was stirred at RT for 2 hours and filtered. NH4PF6 (0.0429 g, 0.263 mmol for [][PF6]4; 0.0420 g, 0.258 mmol for [2][PF6]4; 0.0414 g, 0.254 mmol for [3][PF6]4; 0.0431 g, 0.264 mmol for [4][PF6]4) was added to the filtrate at 0 °C and stirred for 4 hours. An orange-red precipitate was observed. The solid was isolated by filtration, washed with isopropanol and finally with Et2O. The solid was dried in vacuo.

[DB-G7-PFF-[[η^6-p-cymene]Ru([C2H2NO]2-x^2-N,O)-4-ferrocenylpyridine)]4][PF6]4 ([4][PF6]4). Orange solid. Yield: 0.0749 g, 35%. IR (ATR): ν (cm^-1) = 1611 (s & br, imine & pyridine, C=N). H NMR ([CD3]2CO): δ (ppm) = 0.96-1.21 & 1.24-1.32 (br m, 24H, CH(CH2)n-p-cymene), 1.71-2.26 (overlapping m, 24H, CH(CH2)n-p-cymene, NCH2CH3 core, NCH2CH3 CH2Nbranch), 2.51-3.11 (br m, 16H, CH3-p-cymene CH(CH2)2-p-cymene), 3.96 (br s, 20H, Cp-CH3 unsubstit. ring), 4.32-4.64 (overlapping br m, 16H, NCH2CH3CH3Nbranch, Cp-CH), 4.70-4.98 (m, 8H, Cp-CH), 5.54-5.76 (m, 8H, Ar-phenylene), 5.81-6.03 (m, 8H, Ar-phenylene), 6.27-6.41 (m, 4H, Ar), 6.87-7.02 (br m, 8H, 2 × Ar), 7.09-7.24 (m, 4H, Ar), 7.39-7.63 (m, 8H, Pyr), 8.11 (br s, 4H, CH3mine), 8.39-8.55 (m, 8H, Pyr). 13C(1H) NMR ((CD3)2CO): δ (ppm) = 17.0, 21.5, 22.1 (CH3-p-cymene); 50.7, 66.4, 69.7, 70.2, 71.7 (CH2); 67.5, 71.6 (Cp-CH); 70.3 (Cp-CH unsubstit. ring); 78.0 (Cpben); 80.8, 81.0, 84.1, 84.7, 88.8 (CH2phenylene); 99.8, 119.9 (Cphenylene); 113.0, 121.3, 135.0, 135.1 (CH2); 120.0 (Cphenylene); 152.9, 164.9 (Cphenyl); 165.9 (Cphenyl). Elemental analysis for C14H10F24P8Fe4N8O4P8Ru2·2DCM (3424.2436): Found C, 49.86; H, 4.47; N, 3.94%; calcd C, 49.81; H, 4.83; N, 4.09%. MS (HR-ESI-TOF, m/z): 417.8664 [M+4(FcPyr)]+ (where M = [1][PF6]4 - 4PF6).
General synthesis of cationic \( \text{N}_2\text{O}(\text{q}-\text{C}_3\text{Me}_2)\text{-M}(\text{ferrocenylpyridine}) \) metalloendrimers (where \( \text{M} = \text{Ir} \) or \( \text{Rh} \), [5][PF] \(_8\))

[a][DAB-G-PPI-([q]-3-MeC)_6Ir((C_2H_6NO)_2-x-N,4-ferrocenylpyridine)] \(_8\)[PF] \(_4\) \(_n\) \(_b\) \(_a\) \(_d\) \(_e\) \(_f\) \(_g\) \(_h\) \(_i\) \(_j\) \(_k\) \(_l\) \(_m\) \(_n\) \(_o\) \(_p\) \(_q\) \(_r\) \(_s\) \(_t\) \(_u\) \(_v\) \(_w\) \(_x\) \(_y\) \(_z\). \]

Orange solid. Yield: 0.28 g, 56%. MS (HR-ESI-TOF, \( \nu \) cm\(^{-1}\)): 1612 (s & br, imine & pyridine, \( C\text{-N} \)). \( ^1\text{H} \) NMR (\( C\text{D}_2\)O): \( \delta \) ppm = 1.26 (40H, \( CH\text{imine} \)), 2.17 (20H, \( CH\text{imine} \)), 6.50 (20H, \( CH\text{imine} \)), 7.31 (20H, \( CH\text{imine} \)). NMR (\( CD\text{Cl}_2\)): \( \delta \) ppm = 1.26 (40H, \( CH\text{imine} \)), 2.17 (20H, \( CH\text{imine} \)), 6.50 (20H, \( CH\text{imine} \)), 7.31 (20H, \( CH\text{imine} \)).

[a][DAB-G-PPI-([q]-3-MeC)_6Ir((C_2H_6NO)_2-x-N,4-ferrocenylpyridine)] \(_8\)[PF] \(_4\) \(_n\) \(_b\) \(_a\) \(_d\) \(_e\) \(_f\) \(_g\) \(_h\) \(_i\) \(_j\) \(_k\) \(_l\) \(_m\) \(_n\) \(_o\) \(_p\) \(_q\) \(_r\) \(_s\) \(_t\) \(_u\) \(_v\) \(_w\) \(_x\) \(_y\) \(_z\). \]

Orange solid. Yield: 0.28 g, 56%. MS (HR-ESI-TOF, \( \nu \) cm\(^{-1}\)): 1612 (s & br, imine & pyridine, \( C\text{-N} \)). \( ^1\text{H} \) NMR (\( C\text{D}_2\)O): \( \delta \) ppm = 1.26 (40H, \( CH\text{imine} \)), 2.17 (20H, \( CH\text{imine} \)), 6.50 (20H, \( CH\text{imine} \)), 7.31 (20H, \( CH\text{imine} \)). NMR (\( CD\text{Cl}_2\)): \( \delta \) ppm = 1.26 (40H, \( CH\text{imine} \)), 2.17 (20H, \( CH\text{imine} \)), 6.50 (20H, \( CH\text{imine} \)), 7.31 (20H, \( CH\text{imine} \)).
[9][PF6]2-[12]PF6, [9][PF6]2-[12]PF6 were obtained in an analogous manner as [11][PF6]2-[12]PF6, using triethylamine (0.043 mmol, 0.309 mmol for [9][PF6]2, 0.047 mmol, 0.336 mmol for [10][PF6]2, 0.040 mmol, 0.290 mmol for [11][PF6]2, 0.043 mmol, 0.307 mmol for [12][PF6]2, L3 (0.0481 g, 0.295 mmol for [9][PF6]; 0.0523 g, 0.320 mmol for [10][PF6]; 0.0474 g, 0.290 mmol for [11][PF6]; 0.0501 g, 0.307 mmol for [12][PF6]), [n-6η-p-cymene][RuCl]2 (0.0902 g, 0.147 mmol for [9][PF6]2) or [n-η6-HMR][RuCl]2 (0.108 g, 0.160 mmol for [10][PF6]2) or [n-5η6-C5Me5]IrCl2 (0.113 g, 0.142 mmol for [9][PF6]; 0.0523 g, 0.320 mmol for [10][PF6]; 0.0474 g, 0.290 mmol for [11][PF6]; 0.0501 g, 0.307 mmol for [12][PF6]), 4-ferrocyldipyridine (0.0814 g, 0.309 mmol for [9][PF6]; 0.0885 g, 0.336 mmol for [10][PF6]; 0.0764 g, 0.290 mmol for [11][PF6]; 0.0808 g, 0.307 mmol for [12][PF6]) and NH4PF6 (0.0504 g, 0.309 mmol for [9][PF6]; 0.0548 g, 0.336 mmol for [10][PF6]; 0.0473 g, 0.290 mmol for [11][PF6]; 0.0501 g, 0.307 mmol for [12][PF6]).

[CH2CH2CH2(p-6η-p-cymene)Ru(C(H2)NO)x2-N,O]-4-ferrocyldipyridine,[PF6]2-[PF6]2] Red solid. Yield: 0.2152 g, 91%. IR (ATR): ν (cm−1) = 1609 (s & br, imine & pyridine, C=N). 1H NMR ((CD3)2CO): δ (ppm) = 1.09 (t, J = 7.3 Hz, 3H, NCH2CH2CH3), 1.31 & 1.23 (d, J = 6.9 Hz, 6H, CH(CH3)2-p-cymene), 1.82-2.03 (m, 2H, NCH2CH2CH3), 2.83-2.90 (m, 1H, CH-CH2-p-cymene), 3.97 (3H, 5H, Cp-CH3 unsubst. ring), 4.43-4.49 & 4.53-4.59 (m, 2H, NCH2CH2CH3), 4.58 (t, J = 19 Hz, 2H, Cp-CH), 4.97 (t, J = 1.9 Hz, 2H, Cp-CH), 5.70-5.81 (m, 2H, Ar-p-cymene), 5.98-6.10 (m, 2H, Ar-p-cymene), 6.40 (dd, J = 7.9, 8.9, 1.1 Hz, 1H, Ar), 6.94 (J = 8.4 Hz, 1H, Ar), 7.01 (dd, J = 7.9, 1.8 Hz, 1H, Ar), 7.22 (dd, J = 8.5, 1.9 Hz, 1H, Ar), 7.57 (d, J = 6.8 Hz, 2H, Pyr), 8.12 (s, 1H, CH3imine), 8.53 (d, J = 6.8 Hz, 2H, Pyr), 131C[Ar] NMR ((CD3)2CO): δ (ppm) = 10.6 (CH2), 81.1, 21.4, 22.0 (CH3-p-cymene): 25.0, 66.8 (CH3); 67.5, 71.6 (Cp-CH); 70.2 (Cp-CH3 unsubst. ring): 77.9 (Cpβ); 30.8, 83.1, 84.2, 84.5, 89.2 (Cp-imine): 99.9, 119.9 (Cp-CH); 114.9, 121.3, 134.8, 135.0 (CH2); 120.3 (Cpγ); 121.6, 152.5 (Cpβ); 149.6, 164.8 (Cα); 165.9 (CH3imine). Elemental analysis for C36H43F6FeN2O8P [805.8357]: Found: C 52.01; H, 4.81; N, 3.37%; calc d C, 52.18; H, 4.88; N, 3.48%. MS (HR-ESI-TOF, m/z): 398.1064 [M – 4[FePyr]]+ (where M = [9][PF6]2 – PF6).
seeded in 96-well plates as monolayers with 100 μL of cell solution (approximately 10,000 cells) per well and pre-incubated for 24 h in medium supplemented with 10% FBS. Compounds were prepared as DMSO solution, then dissolved in the culture medium and immediately serially diluted to the appropriate concentration, to give a final DMSO concentration of 0.5%. A 100 μL portion of drug solution was added to each well and the plates were incubated for another 72 h. Subsequently, MTT (5 mg mL⁻¹ solution in PBS) was added to the cells and the plates were incubated for a further 4 h. The culture medium was aspirated, and the purple formazan crystals formed by the mitochondrial dehydrogenase activity of vital cells were dissolved in DMSO. The optical density, directly proportional to the amount of dead cells, against the log of drug concentration was measured using a multiwell plate reader and the fraction of surviving cells was calculated from the absorbance of untreated control cells. The IC₅₀ values were determined by fitting the plot of the log of the ratio between the percentages of surviving cells, divided by the amount of dead cells, against the log of drug concentration using a linear threshold function. Evaluation is based on means from at least two independent experiments, each comprising four microcultures per concentration level.

NMR studies
For the stability/aquation studies, second generation metallo-dendrimer [4][PF₆]₈ and its closest binuclear analogue [10][PF₆] was dissolved in DMSO-d₆ and D₂O (50:50% v/v, because of limited solubility), warmed at 37 °C (to mimic physiological temperature) before samples were monitored using ¹H and ³¹P{¹H} NMR experiments at 37 °C over 24 hours on a Bruker Biospin GmbH spectrometer (¹H: 400.22 MHz, ³¹P{¹H}: 162.00 MHz).

UV-Vis studies
Absorption studies of a 0.23 mM and 0.15 mM solution of [4][PF₆]₈ and [10][PF₆] respectively in H₂O with 0.22 mM HEPES buffer, pH 6.3 were performed in the range 225–345 nm. Solutions of Red Salmon testes DNA sodium salt were prepared fresh before each experiment using milli-Q water. 50 μL aliquots of 50 nM DNA stock solution were added to [4][PF₆]₈ and [10][PF₆] to make the DNA concentrations: 2.38, 4.55, 6.52, 8.33, 10.0, 11.5, 13.0 and 14.3 nM (for [4][PF₆]₈ & [10][PF₆]) and a further 15.5 and 16.7 nM (for [10][PF₆]).

Conflict of interest
The authors declare no competing financial interest.

Acknowledgements
Financial support from the University of Cape Town, the National Research Foundation (NRF) of South Africa and EPFL is acknowledged. This work is based on the research supported wholly/in part by the National Research Foundation of South Africa (Grant Number: 90500).
O. B. Bychenko and P. M. Raevskii, *Appl. Organomet. Chem.*, 1993, 7, 85–94.

22 P. Köpf-Maier, H. Köpf and E. W. Neuse, *J. Cancer Res. Clin.*, 1984, 108, 336–340.

23 A. Nguyen, A. Vessieres, E. A. Hillard, S. Top, P. Pigeon and G. Jaouen, *Chimia*, 2007, 61, 716–724.

24 S. Top, A. Vessières, C. Cabestaing, I. Laios, G. Leclereq, C. Provot and G. Jaouen, *J. Organomet. Chem.*, 2001, 637–639, 500–506.

25 E. A. Hillard, A. Vessières, F. Le Bideau, D. Plazul, D. Spera, M. Huché and G. Jaouen, *ChemMedChem*, 2006, 1, 551–559, and references therein.

26 P. Wardman and L. P. Candeias, *Radiat. Res.*, 1996, 145, 523–531.

27 M. Gordon and S. Hollander, *J. Med. Chem.*, 1993, 24, 209–265.

28 N. J. Wheate, S. Walker, G. E. Craig and R. Oun, *Dalton Trans.*, 2010, 39, 8113–8127.

29 C. S. Allardyce and P. J. Dyson, *Dalton Trans.*, 2016, 45, 3201–3209.

30 G. Palermo, A. Magistrato, T. Riedel, T. von Erlach, C. A. Davey, P. J. Dyson and U. Rothlisberger, *ChemMedChem*, 2015, DOI: 10.1002/cmdc.201500478.

31 M. Pongratz, P. Schluga, M. A. Jakupec, V. B. Arion, C. G. Hartinger, G. Palermo, A. Magistrato, T. Riedel, T. von Erlach, C. A. Davey, P. J. Dyson and U. Rothlisberger, *ChemMedChem*, 2015, DOI: 10.1002/cmdc.201500478.

32 P. He.

33 M. J. Clarke, F. C. Zhu and D. R. Frasca, *Chem. Rev.*, 1999, 99, 2511–2533.

34 C. G. Hartinger, M. A. Jakupec, S. Zorbas-Seifried, M. Groessl, A. Egger, W. Berger, H. Zorbas, P. J. Dyson and B. K. Keppler, *Chem. Biodiversity*, 2008, 5, 2140–2155.

35 S. Leijen, S. A. Burgers, P. Baas, D. Pluim, M. Tibben, E. Van Werkhoven, E. Alessio, G. Sava, J. H. Beijnen and J. H. M. Schellens, *Invest. New Drugs*, 2015, 33, 201–214.

36 A. L. Nolfke, A. Habtemariam, A. M. Pizarro and P. J. Sadler, *Chem. Commun.*, 2012, 48, 5219–5226.

37 G. Süss-Fink, *Dalton Trans.*, 2010, 39, 1673–1688.

38 A. A. Nazarov, C. G. Hartinger and P. J. Dyson, *J. Organomet. Chem.*, 2014, 751, 251–260.

39 I. Bratsos, T. Gianferrara, E. Alessio, C. G. Hartinger, M. A. Jakupec and B. K. Keppler, in *Bioinorganic Medicinal Chemistry*, ed. E. Alessio, Wiley-VCH, Weinheim, 2011, pp. 151–174.

40 H.-K. Liu and P. J. Sadler, *Acc. Chem. Res.*, 2011, 44, 349–359.

41 M. A. Jakupec, M. Galanski, V. B. Arion, C. G. Hartinger and B. K. Keppler, *Dalton Trans.*, 2008, 183–194.

42 W. H. Ang, A. Casini, G. Sava and P. J. Dyson, *J. Organomet. Chem.*, 2011, 696, 989–998.

43 R. E. Morris, R. E. Aird, P. D. S. Murdoch, H. Chen, J. Cummings, N. D. Hughes, S. Parsons, A. Parkin, G. Boyd, D. I. Jodrell and P. J. Sadler, *J. Med. Chem.*, 2001, 44, 3616–3621.

44 R. E. Aird, J. Cummings, A. A. Ritchie, M. Muir, R. E. Morris, H. Chen and P. J. Sadler, *Br. J. Cancer*, 2002, 86, 1652–1657.

45 C. Scolaro, A. Bergamo, L. Brescacin, R. Delfino, M. Cocchietto, G. Laurenczy, T. J. Geldbach, G. Sava and P. J. Dyson, *J. Med. Chem.*, 2005, 48, 4161–4171.

46 A. Bergamo, A. Masi, P. J. Dyson and G. Sava, *Int. J. Oncol.*, 2008, 33, 1281–1289.

47 Z. Adhireksan, G. E. Davey, P. Campomanes, M. Groessl, C. M. Clavel, H. Yu, A. A. Nazarov, C. H. F. Yeo, W. H. Ang, P. Droege, U. Rothlisberger, P. J. Dyson and C. A. Davey, *Nat. Commun.*, 2014, 5, 3462.

48 S. Chatterjee, S. Kundu, A. Bhattacharyya, C. G. Hartinger and P. J. Dyson, *J. Biol. Inorg. Chem.*, 2008, 13, 1149–1155.

49 A. Weiss, R. H. Berndsen, M. Dubois, M. Muller, R. Schibli, A. W. Griffioen, P. J. Dyson and P. Nowak-Sliwinska, *Chem. Sci.*, 2014, 5, 4742–4728.

50 A. Weiss, X. Ding, J. R. van Berijn, I. Wong, T. J. Wong, R. H. Berndsen, O. Dormond, M. Dallinga, L. Shen, R. O. Schilingemann, R. Pili, C.-M. Ho, P. J. Dyson, H. van den Bergh, A. W. Griffioen and P. Nowak-Sliwinska, *Angiogenesis*, 2015, 18, 233–244.

51 A. Weiss, D. Bonvin, R. H. Berndsen, E. Scherrer, T. J. Wong, P. J. Dyson, A. W. Griffioen and P. Nowak-Sliwinska, *Sci. Rep.*, 2015, 5, 8990.

52 P. Nowak-Sliwinska, J. R. van Beijnum, A. Casini, A. A. Nazarov, G. Wagnières, H. van den Bergh, P. J. Dyson and A. W. Griffioen, *J. Med. Chem.*, 2011, 54, 3895–3902.

53 I. Romero-Canelon and P. J. Sadler, *Inorg. Chem.*, 2013, 52, 12276–12291.

54 L. Roeglin, E. H. M. Lepens and E. W. Meijer, *Angew. Chem., Int. Ed.*, 2011, 50, 102–112.

55 O. Dömötör, S. Aicher, M. Schmidlehner, M. S. Novak, A. Roller, M. A. Jakupec, W. Kandiolier, C. G. Hartinger, B. K. Keppler and E. A. Enyedy, *J. Inorg. Biochem.*, 2014, 134, 57–65.

56 J. Ruiz, V. Rodriguez, N. Cutillas, K. G. Samper, M. Capdevilla, O. Palacios and A. Espinosa, *Dalton Trans.*, 2012, 41, 12847–12856.

57 O. Domotor, S. Aicher, M. Schmidlehner, A. Roller, M. A. Jakupec, W. Kandiolier, C. G. Hartinger, B. K. Keppler and E. A. Enyedy, *J. Inorg. Biochem.*, 2014, 134, 57–65.

58 G. Gupta, G. Sharma, B. Koch, S. Park, S. S. Lee and J. Kim, *New J. Chem.*, 2013, 37, 2573–2581.

59 P. Govender, B. Therrien and G. S. Smith, *Eur. J. Inorg. Chem.*, 2012, 2835–2862, DOI: 10.1002/ejic.201200161.

60 G. S. Smith and B. Therrien, *Dalton Trans.*, 2011, 40, 10793–10800.

61 S. K. Singh and D. S. Pandey, *RSC Adv.*, 2014, 4, 1819–1840.

62 K. Wang and E. Gao, *Anti-Cancer Agents Med. Chem.*, 2014, 14, 147–169.

63 C. G. Hartinger, A. D. Phillips and A. A. Nazarov, *Curr. Top. Med. Chem.*, 2011, 11, 2688–2702.

64 M. G. Mendoza-Ferri, C. G. Hartinger, M. A. Mendoza, M. Groessl, A. Egger, R. E. Eichinger, J. B. Mangrum,
N. P. Farrell, M. Maruszak, P. J. Bednarski, F. Klein, M. A. Jakupec, A. A. Nazarov, K. Severin and B. K. Kepller, J. Med. Chem., 2009, 52, 916–925.

65 M. G. Mendoza-Ferri, C. G. Hartinger, R. Eichinger, N. Stolyarova, K. Severin, M. A. Jakupec, A. A. Nazarov and B. K. Kepller, Organometallics, 2008, 27, 2405–2407.

66 N. Farrell, Met. Ions Biol. Syst., 2004, 42, 251–296.

67 A. Casini, M. A. Cinellu, G. Minghetti, C. Gabbiani, M. Coronello, E. Mini and L. Messori, J. Med. Chem., 2006, 49, 5524–5531.

68 C. Gabbiani, A. Casini, L. Messori, A. Guerri, M. A. Cinellu, G. Minghetti, M. Corsini, C. Rosani, P. Zanello and M. Arca, Inorg. Chem., 2008, 47, 2368–2379.

69 M. A. Cinellu, L. Maiore, M. Manassero, A. Casini, M. Arca, H. H. Fiebig, G. Kelter, E. Michelucci, G. Pieraccini, C. Gabbiani and L. Messori, Med. Chem. Lett., 2010, 1, 336–339.

70 B. C. E. Makhubela, M. Meyer and G. S. Smith, J. Organomet. Chem., 2014, 772–773, 229–241.

71 A. R. Burgoyne, B. C. E. Makhubela, M. Meyer and G. S. Smith, Eur. J. Inorg. Chem., 2015, 1433–1444.

72 P. Govender, F. Edafe, B. C. E. Makhubela, P. J. Dyson, B. Therrien and G. S. Smith, Inorg. Chim. Acta, 2014, 409, 112–120.

73 P. Govender, L. C. Sudding, C. M. Clavel, P. J. Dyson, B. Therrien and G. S. Smith, Dalton Trans., 2013, 42, 1267–1277.

74 R. Payne, P. Govender, B. Therrien, C. M. Clavel, P. J. Dyson and G. S. Smith, J. Organomet. Chem., 2013, 729, 20–27.

75 L. C. Sudding, R. Payne, P. Govender, F. Edafe, C. M. Clavel, P. J. Dyson, B. Therrien and G. S. Smith, J. Organomet. Chem., 2014, 774, 79–85.

76 T. Ahamad, S. F. Mapolie and S. M. Alshehri, Med. Chem. Res., 2010, 138, 171–179.

77 S. El Kazzouli, N. El Brahmi, S. Migiani, M. Bousmina, M. Zablocka and J.-P. Majoral, Curr. Med. Chem., 2012, 19, 4995–5010.